These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

766 related articles for article (PubMed ID: 27067394)

  • 1. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
    Dummer R; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Gogov S; Pallaud C; Yi T; Mone M; Chang AL; Cornélis F; Kudchadkar R; Trefzer U; Lear JT; Sellami D; Migden MR
    J Am Acad Dermatol; 2016 Jul; 75(1):113-125.e5. PubMed ID: 27067394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study.
    Dummer R; Guminksi A; Gutzmer R; Lear JT; Lewis KD; Chang ALS; Combemale P; Dirix L; Kaatz M; Kudchadkar R; Loquai C; Plummer R; Schulze HJ; Stratigos AJ; Trefzer U; Squittieri N; Migden MR
    Br J Dermatol; 2020 Jun; 182(6):1369-1378. PubMed ID: 31545507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.
    Migden MR; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kudchadkar R; Trefzer U; Gogov S; Pallaud C; Yi T; Mone M; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Chang AL; Cornélis F; Lear JT; Sellami D; Dummer R
    Lancet Oncol; 2015 Jun; 16(6):716-28. PubMed ID: 25981810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study.
    Lear JT; Migden MR; Lewis KD; Chang ALS; Guminski A; Gutzmer R; Dirix L; Combemale P; Stratigos A; Plummer R; Castro H; Yi T; Mone M; Zhou J; Trefzer U; Kaatz M; Loquai C; Kudchadkar R; Sellami D; Dummer R
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):372-381. PubMed ID: 28846163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.
    Danial C; Sarin KY; Oro AE; Chang AL
    Clin Cancer Res; 2016 Mar; 22(6):1325-9. PubMed ID: 26546616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of advanced basal cell carcinoma with sonidegib: perspective from the 30-month update of the BOLT trial.
    Chen L; Aria AB; Silapunt S; Lee HH; Migden MR
    Future Oncol; 2018 Mar; 14(6):515-525. PubMed ID: 29119833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
    Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
    J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.
    Jacobsen AA; Aldahan AS; Hughes OB; Shah VV; Strasswimmer J
    JAMA Dermatol; 2016 Jul; 152(7):816-24. PubMed ID: 27096888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month update.
    Chen L; Silapunt S; Migden MR
    Future Oncol; 2016 Sep; 12(18):2095-105. PubMed ID: 27189494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Not Available].
    Basset-Seguin N
    Ann Dermatol Venereol; 2018 Nov; 145 Suppl 5():VS36-VS41. PubMed ID: 30477683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma.
    Collier NJ; Ali FR; Lear JT
    Expert Rev Anticancer Ther; 2016 Oct; 16(10):1011-8. PubMed ID: 27636236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.
    Rodon J; Tawbi HA; Thomas AL; Stoller RG; Turtschi CP; Baselga J; Sarantopoulos J; Mahalingam D; Shou Y; Moles MA; Yang L; Granvil C; Hurh E; Rose KL; Amakye DD; Dummer R; Mita AC
    Clin Cancer Res; 2014 Apr; 20(7):1900-9. PubMed ID: 24523439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis.
    Gutzmer R; Robert C; Loquai C; Schadendorf D; Squittieri N; Arntz R; Martelli S; Dummer R
    BMC Cancer; 2021 Nov; 21(1):1244. PubMed ID: 34798846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
    Dessinioti C; Plaka M; Stratigos AJ
    Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma.
    Migden M; Farberg AS; Dummer R; Squittieri N; Hanke CW
    J Drugs Dermatol; 2021 Feb; 20(2):156-165. PubMed ID: 33538567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expert opinion on sonidegib efficacy, safety and tolerability.
    Villani A; Fabbrocini G; Costa C; Ocampo-Garza SS; Lallas A; Scalvenzi M
    Expert Opin Drug Saf; 2021 Aug; 20(8):877-882. PubMed ID: 33888008
    [No Abstract]   [Full Text] [Related]  

  • 17. Hedgehog Pathway Inhibition.
    Sekulic A; Von Hoff D
    Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis.
    Xie P; Lefrançois P
    J Am Acad Dermatol; 2018 Dec; 79(6):1089-1100.e17. PubMed ID: 30003981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.
    Lacouture ME; Dréno B; Ascierto PA; Dummer R; Basset-Seguin N; Fife K; Ernst S; Licitra L; Neves RI; Peris K; Puig S; Sokolof J; Sekulic A; Hauschild A; Kunstfeld R
    Oncologist; 2016 Oct; 21(10):1218-1229. PubMed ID: 27511905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sonidegib: A Review in Locally Advanced Basal Cell Carcinoma.
    Burness CB; Scott LJ
    Target Oncol; 2016 Apr; 11(2):239-46. PubMed ID: 26867946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.